Mereo BioPharma (MREO) Total Liabilities (2017 - 2026)

Mereo BioPharma (MREO) has reported Total Liabilities for 10 consecutive years, with $6.6 million the latest figure, recorded in Q1 2026.

• Quarterly Total Liabilities fell 20.4% year-over-year to $6.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.6 million (down 20.4% YoY) and the FY2025 annual result came in at $5.0 million, down 67.57% from the prior year.
• Total Liabilities improved to $6.6 million in Q1 2026 per MREO's latest filing, from $5.0 million in the prior quarter.
• Over the last five years, Total Liabilities for MREO reached as high as $48.4 million in Q2 2022 and fell as low as $5.0 million in Q4 2025.
• A 5-year average of $17.0 million and a median of $15.4 million in 2024 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2024 — Total Liabilities fell 3.39% — and 2025, when it tumbled 67.57%.
• Year by year, Total Liabilities stood at $30.7 million in 2022, then tumbled by 48.08% to $16.0 million in 2023, then decreased by 3.39% to $15.4 million in 2024, then slumped by 67.57% to $5.0 million in 2025, then surged by 31.17% to $6.6 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $6.6 million, $5.0 million, and $7.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.